Analysis of Liver Function on Leprosy Patient with Multidrug Therapy in Haji Adam Malik General Hospital Medan from January until December 2017

Mila Darmi; Ramona Dumasari Lubis

doi:10.3889/oamjms.2020.3258

Authors

Mila Darmi Department of Dermatology and Venereology, Haji Adam Malik General Hospital, Medan, Indonesia
Ramona Dumasari Lubis Department of Dermatology and Venereology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.3258

Keywords:

leprosy, liver function test, hepatotoxicity, multidrug therapy, side effects

Abstract

Leprosy is a chronic progressive granulomatous disease that caused by Mycobacterium leprae, an intracellular obligate bacteria. Leprosy can be treated using multidrug therapy (MDT) that can be associated with hepatotoxicity as their side effects. We included 14 patients that were all diagnosed with multibacillary leprosy, but with four drops out persons. Liver function evaluations before MDT were in the normal range. After 1st, 2nd, and 3rd months of MDT, liver function test in research subjects also in the normal range even though there is variation in this value. There is a risk of hepatotoxicity of MDT; therefore, liver function test should be done periodically for early detection of any liver dysfunction.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Swathi M. A study of liver function test in leprosy. Indian J Lepr. 2014;86(4):155-7. PMid:26411248

Infodatin. Pusat Data dan Informasi Kementerian Kesehatan RI; 2015. Available from: http://www.depkes.go.id. [Last accessed on 2015 Nov 23].

Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia. Data dan Informasi Tahun 2014; 2015. Available from: http://www.depkes.go.id. [Last accessed on 2015 Nov 23].

Noordin SK. Leprosy control through multi drug therapy (MDT). Bull World Health Organ. 1999;69:263-9. PMid:1893503

World Health Organization. Leprosy Today. Geneva: World Health Organization; 2014. Available from: http: www.who.int/ lep/en. [Last accessed on 2014 Dec 01].

Baymakova M. Fever of unknown origin in adults. Gen Med. 2015;17:61-8.

Krishnan SP, Kamalanathan A, John J, Gopalakrishnan S. A reminiscent review on leprosy. Med Microbiol. 2015;26:8-13.

Singh H, Nel B, Dey V, Tiwari P, Dulhani N. Adverse effect of multi drug therapy in leprosy, a two yearsâ€™ experience (2006- 2008) in tertiary health care in the tribal region of Chhattisgarh state (Bastar, Jagdalpur). Lepr Rev. 2011;82(1):17-24. https:// doi.org/10.4103/1755-6783.77188 PMid:21644468

Kar HK, Gupta R. Treatment of leprosy. Clin Dermatol. 2015;33(1):55-65. PMid:25432811

Alberto C, Michele B. Drug-induced liver injury: The role of drug metabolism and transport. J Clin Pharmacol. 2013;53(5):463-74. PMid:23436293

Dhavalshankh GP, Dhavalshankh AG, Gaurkar S. Assessment and comparison of liver functions in leprosy. Int J Cur Res Rev. 2017;9(5):26-32.

Bjornsson E, Olsson R. Outcome and prognostic markers in serve drug-induced liver disease. Hepatology. 2005;42(2):481- 9. https://doi.org/10.1002/hep.20800 PMid:16025496

Tsankov N, Kamarashev J. Rifampin in dermatology. Int J Dermatol. 1993;32(6):401-6. https://doi.org/10.1111/j.1365-4362.1993. tb02807.x PMid:8320018

Ferrari T, Araujo M, Ribeiro M. Hepatic involvement in lepromatous leprosy. Lepr Rev. 2002;73:72-5. PMid:11969129

Wakelin SH, Maibach H, Archer C. Handbook of Systematic Drug Treatment in Dermatology. 2nd ed., Vol. 118. New York: Free Press; 1998. p. 629-34.

Li HY, Yu XL, Zhang MS, Duan CX, Huang WB, Zhang SB, et al. Short-term multidrug therapy in multibacililary leprosy review of 80 case in two provinces of China (1983-1988). Int J Lepr.1988;57(3):622-7. PMid:2778368

Moet FJ, Meima A, Oskam L, dan Richardus JH. Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. Lepr Rev. 2004;75:310-26. PMid:15682969

Baymakova M, Zaekov N, Andonova R, Pishmisheva M, Pekova L, Popov GT, et al. Infectious diseases in athletes. Gen Med. 2017;19(2):50-6. PMid:21623289

Venkatesan K, Neo D. Biochemical aspects of leprosy. In: Kumar B, Kar HK, editors. IAL Textbook of Leprosy. Vol. 2. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2016. p. 125. https://doi.org/10.5005/jp/books/12958_9

Nigam PK, Gupta GB, Khare A. Hepatic involvement and hepatitis B surface antigen (Hbs Ag) in leprosy. Indian J Dermatol Venereol Leprol. 2003;69(1):32-4. PMid:17642821

Deps PD, Nasser S, Guerra P, Simon M, Birshner RD, Rodrigues KC. Adverse effect from multi-drug therapy in leprosy: A Brazilian study. Lepr Rev. 2007;78(3):216-22. PMid:18035772

Pollock NR, Rolland JP, Kumar S, Beattie PD, Jain S, Noubary F, et al. A paper based multiplexed transaminase test for low cost, point of care liver function testing. Sci Transl Med. 2012;4(152):1-11. https://doi.org/10.1126/scitranslmed.3003981

Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J. 2003;79(932):307-12. PMid:12840117

Wilcock A, Howard P. Rifampicin (INN Rifampicin). J Pain Symptom Manage. 2015;50(6):891-5. https://doi.org/10.1016/j.jpainsymman.2015.09.004 PMid:26432572

Gothwal S, Khosya S, Gharpure N. Dapsone hypersensitivity syndrome a fatal adverse drug reaction. Intern Med. 2013;3(1):1-5.